Everything below concerns Pharmacokinetics. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
== Production == Aerated chocolate containing large bubbles is produced via two methods. In the first, melted chocolate is put under a vacuum, where it foams up. As the chocolate cools, and the fats within the chocolate set, the foam structure remains. Sometimes gases such as carbon dioxide are introduced into the mixture before it is placed under the vacuum. Although the method easily permits inclusions such as nougat or nuts, the production is labor-intensive and difficult to keep hygienic. As a result, the second method is more frequently used: working gases into liquid, tempered chocolate under high pressure. Carbon dioxide is mainly used, although others include nitrous oxide. Air is avoided, as oxygen causes chocolate to become rancid. Any gases that do not dissolve are dispersed as bubbles through the chocolate using a beater. As the chocolate is released from the high pressure conditions, the bubbles expand, foaming the product; through this, the amount of pressure directly impacts bubble size. The setting chocolate is deposited in a moulded shell, after which the set interior is capped with liquid tempered chocolate. Factors that affect bubble size include qualities of chocolate, such as viscosity and the rate of setting. The ingredients used, such as emulsifiers and milk fats also impact bubble size; other factors include type of gas and how much pressure is applied. Micro-aerated chocolate is created using the method of beating gases in under high pressure.
On 13 September 1880, a 212-man unit of Cape Mounted Riflemen under Lieutenant Colonel Frederick Carrington crossed into Basutoland in the vicinity of Wepener in order to reinforce the isolated magistracy at Mafeteng. Upon hearing of Carrington's advance, the Mafeteng District magistrate Arthur Barkly set off with 20 policemen to scout ahead. Some 2 miles (3.2 km) from the magistracy, he encountered 300 Basuto warriors commanded by Lerotholi on a hill range overlooking the road. The two parleyed, and Barkly informed Lerotholi of the column's imminent approach and advised him to surrender his arms and withdraw. Lerotholi refused and rode back to his men, after seeing the CMR appear on the rear of the police force. The Basuto then charged down from the hill, and a short skirmish ensued whereby the Basuto suffered light casualties. Carrington's troops then garrisoned Mafeteng, where they were besieged by Lerotholi. On 17 September, a CMR unit was attacked by 700 Basuto outside Mafeteng. Following this attack Sprigg ordered the mobilization of the Cape's armed forces. The army mustered by the Cape government for the conflict, consisting entirely of Cape Colonial Forces troops, was commanded by Brigadier General Charles Clarke, who visited the frontlines only twice during the war, relegating his responsibilities to Adjutant General Major W. F. D. Cochrane and Carrington. Carrington was appointed as the Commandant of the Mafeteng Region and entrusted with a force of approximately 2,000 men.
Some gas panels have a separate supply gauge for each diver downstream of the supply valve, but this is not standard practice. The gas panel may be fairly large and mounted on a board for convenience of use, or may be compact and mounted inside a portable box, for ease of transport. Gas panels are usually for one, two or three divers. In some countries, or under some codes of practice, the surface standby diver must be supplied from a separate panel to the working diver/s. A wet or closed bell will be fitted with a bell gas panel to supply gas to the divers' excursion umbilicals. The bell gas panel is supplied with primary gas from the surface via a bell umbilical, and on-board emergency gas from high-pressure storage cylinders mounted on the frame of the bell.
Sources: en.wikipedia.org
Elevated concentrations of 210Po in tobacco were documented as early as 1964, and cigarette smokers were thus found to be exposed to considerably greater doses of radiation from 210Po and its parent 210Pb. Heavy smokers may be exposed to the same amount of radiation (estimates vary from 100 µSv to 160 mSv per year) as individuals in Poland were from Chernobyl fallout traveling from Ukraine. As a result, 210Po is most dangerous when inhaled from cigarette smoke.
== Medical uses == Metformin is used to lower blood glucose in those with type 2 diabetes. It has also been used to help with metabolic abnormalities in polyendocrine metabolic ovarian syndrome (PMOS), and as a second-line agent for infertility in those with PMOS.
Fed-batch fermentation is a variation of batch fermentation where some of the ingredients are added during the fermentation. This allows greater control over the stages of the process. In particular, production of secondary metabolites can be increased by adding a limited quantity of nutrients during the non-exponential growth phase. Fed-batch operations are often sandwiched between batch operations.
== Metabolism == Isoniazid reaches therapeutic concentrations in serum, cerebrospinal fluid, and within caseous granulomas. It is metabolized in the liver via acetylation into acetylhydrazine. Two forms of the enzyme are responsible for acetylation, so some patients metabolize the drug more quickly than others. Hence, the half-life is bimodal, with "slow acetylators" and "fast acetylators". A graph of number of people versus time shows peaks at one and three hours. The height of the peaks depends on the ethnicities of the people being tested. The metabolites are excreted in the urine. Doses do not usually have to be adjusted in case of renal failure.
Sources: en.wikipedia.org
Typically, women with GDM exhibit no symptoms (another reason for universal screening), but some women may demonstrate increased thirst, increased urination, fatigue, nausea and vomiting, bladder infection, yeast infections and blurred vision. Pregnant women with these risk factors may need to undergo an early screening in addition to the routine screening.
=== Superhydrophobic surfaces === A superhydrophobic surface is a low energy, generally rough surface on which water has a contact angle of >150°. Nonpolar materials such as hydrocarbons traditionally have relatively low surface energies, however, this property alone is insufficient to achieve superhydrophobicity. Superhydrophobic surfaces can be created in many ways, however, most of the synthesis strategies are inspired by natural designs. The Cassie-Baxter model provides an explanation for superhydropbicity—air trapped in microgrooves of a rough surface creates a "composite" surface consisting of air and the tops of microprotrusions. This structure is maintained as the scale of the features decreases, thus many approaches to the synthesis of superhydrophobic surfaces have focused on the fractal contribution. Wax solidification, lithography, vapor deposition, template methods, polymer reconfirmation, sublimation, plasma, electrospinning, sol-gel processing, electrochemical methods, hydrothermal synthesis, layer-by-layer deposition, and one-pot reactions are approaches to the creation of superhydrophobic surfaces that have been suggested. Making a surface superhydrophobic represents an efficient means of imparting antimicrobial activity. A passive antibacterial effect results from the poor ability of microbes to adhere to the surface. The area of superhydrophobic textiles takes advantage of this and could have potential applications as antimicrobial coatings.
Ensuring data privacy and security: Farmers have concerns about who can access their data. Their concerns extend to government use of data; German farmers reported a "lack of data security and excessive transparency vis-à-vis the public authorities." Scholars have issued repeated calls for policymakers to address agricultural data privacy and security. Address data ownership: According to the European Parliamentary Research Service, "it is clear that the farmer owns the data generated on his fields." The German Agricultural Society and others concur. However, in practice, farmers lack control over data about themselves and their farms. Besides establishing regulations to boost stakeholder confidence, policymakers can harness digital agriculture for the provision of public goods. First, the United Nations' Global Open Data for Agriculture and Nutrition (GODAN) calls for open access to agricultural data as a basic right. Rather than stakeholders operating in "data silos," where no one shares information for fear of competition, open data sources (when appropriately anonymized) can foster collaboration and innovation. Open-sourced data can rebalance the power asymmetry between farmers and large agribusinesses who collect data. Second, governments can finance research and development of digital agriculture.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.